Christopher Kratochvil, M.D., has conducted clinical trials for the past 10 years and he’s loved it.
 |
Christopher Kratochvil, M.D. |
Dr. Kratochvil’s research group studies treatments for children and adolescents with mental illness. He focuses primarily on pharmacotherapies, both alone and in combination with psychotherapy.
He and his team were part of the largest National Institutes of Health-funded clinical trial on adolescence depression. The study helped define current treatment guidelines for clinically depressed adolescents.
Dr. Kratochvil also helped develop atomoxetine (Strattera), a non-stimulant medicine approved to treat attention-deficit/hyperactivity disorder. He was involved beginning with the first multisite clinical trial, conducted numerous subsequent trials and consulted with the pharmaceutical company Eli Lilly that created the drug.
|
“The researchers here do amazing work, and our reputation has helped poise us to expand even further in the arena of medical research,” he said.
Jim Linder, M.D., chief executive officer of UNeMed Corporation and professor of pathology and microbiology, led the search committee that picked Dr. Kratochvil for the position. He said Dr. Kratochvil is ideally qualified to lead this clinical research initiative.
“He has a broad experience as a funded clinical researcher, administrative leader and collaborator with pharmaceutical development,” he said.